Founded in 1998, Junye Pharm provides one-stop intelligent manufacturing services for steroid hormone APIs to the global pharmaceutical industry. The company has established two core production employs over 800 staff members and has total assets exceeding RMB 1.8 billion.

Focused on its core business of steroid hormone APIs, Junye Pharm has built a comprehensive product portfolio covering leading products such as Drospirenone and Mifepristone. Its production volume ranks steadily among the top tier both domestically and internationally, serving more than 200 partners across over 60 countries worldwide. Leveraging its all-round "product + service" model, sound quality management system, sufficient production capacity, and global sales network, the company has emerged as a key player in China's specialty API sector and continues to advance the upgrading of manufacturing toward continuity, automation, digitalization, and intelligence.

Backed by high-end R&D platforms including the National Enterprise Technology Center and CNAS-accredited laboratories, as well as a professional R&D team with superb technical expertise, Junye Pharmaceutical boasts outstanding innovation capabilities. The company has successively won multiple honors such as being recognized as a National "Little Giant" Enterprise (for specialized, refined, distinctive, and innovative enterprises) and the National Excellent Patent Award, and has undertaken more than 20 national-level scientific research projects.

Looking ahead to the future, Junye Pharmaceutical will take technological innovation and digital empowerment as its dual drivers, focus on high-end biomanufacturing, optimize product quality, improve production efficiency, and promote green transformation. Adhering to its vision of "Refining steroid pharmaceuticals and contributing Junye's strength to global health", the company is committed to becoming a leading enterprise in the global steroid drug field.